ಲೋಡ್ ಆಗುತ್ತಿದೆ
x
ಈ ವೆಬ್‌ಸೈಟ್ ಅಗತ್ಯ ಕುಕೀಗಳನ್ನು ಬಳಸುತ್ತದೆ. ನಿಮ್ಮ ಒಪ್ಪಿಗೆಯೊಂದಿಗೆ, ನಾವು ಅಂಕಿಅಂಶಗಳಿಗಾಗಿ Google Analytics ಕುಕೀಗಳನ್ನು ಇರಿಸುತ್ತೇವೆ.

ಗಾಗಿ ಕುಕೀ ನೀತಿ Slzii.com

ಇದು ಕುಕೀ ನೀತಿಯಾಗಿದೆ Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

ಹುಡುಕು (ಸುದ್ದಿ)

ನೆದರ್ಲ್ಯಾಂಡ್ಸ್ | ಬೆಲ್ಜಿಯಂ | ಕುರಾಕೋ | ಥೈಲ್ಯಾಂಡ್ | ನೈಜೀರಿಯಾ | ಜರ್ಮನಿ | ಸ್ಪೇನ್ | ಮೆಕ್ಸಿಕೋ | ಕೊಲಂಬಿಯಾ | ವೆನೆಜುವೆಲಾ | ಅರ್ಜೆಂಟೀನಾ | ಉರುಗ್ವೆ | ಚಿಲಿ | ಈಕ್ವೆಡಾರ್ | ಪೋರ್ಟೊ ರಿಕೊ | ಪೆರು | ಕ್ಯೂಬಾ | ಬೊಲಿವಿಯಾ | ಕೋಸ್ಟರಿಕಾ | ಡೊಮಿನಿಕನ್ ರಿಪಬ್ಲಿಕ್ | ಎಲ್ ಸಾಲ್ವಡಾರ್ | ಗ್ವಾಟೆಮಾಲಾ | ಹೊಂಡುರಾಸ್ | ನಿಕರಾಗುವಾ | ಪರಾಗ್ವೆ | ಪನಾಮ | ಫ್ರಾನ್ಸ್ | ಐವರಿ ಕೋಸ್ಟ್ | ಮೊನಾಕೊ | ಕ್ಯಾಮರೂನ್ | ಕಾಂಗೋ ಗಣರಾಜ್ಯ | ಗ್ಯಾಬೊನ್ | ಸೆನೆಗಲ್ | ಬೆನಿನ್ | ಈಜಿಪ್ಟ್ | ಯುನೈಟೆಡ್ ಅರಬ್ ಎಮಿರೇಟ್ಸ್ | ಕತಾರ್ | ಸೌದಿ ಅರೇಬಿಯಾ | ಮೊರಾಕೊ | ಇರಾಕ್ | ಟುನೀಶಿಯಾ | ಸುಡಾನ್ | ಯೆಮೆನ್ | ಬಹ್ರೇನ್ | ಇರಾನ್ | ಬ್ರೆಜಿಲ್ | ಪೋರ್ಚುಗಲ್ | ಐಸ್ಲ್ಯಾಂಡ್ | ನಾರ್ವೆ | ಚೀನಾ | ತೈವಾನ್ | ಹಾಂಗ್ ಕಾಂಗ್ | ಮಕಾವು | ಇಸ್ರೇಲ್ | ನೇಪಾಳ | ಜೆಕ್ ರಿಪಬ್ಲಿಕ್ | ಪೋಲೆಂಡ್ | ಇಟಲಿ | ಬಾಂಗ್ಲಾದೇಶ | ವಿಯೆಟ್ನಾಂ | ಟರ್ಕಿ | ಮಲೇಷ್ಯಾ | ಬ್ರೂನಿ | ದಕ್ಷಿಣ ಕೊರಿಯಾ | ಉತ್ತರ ಕೊರಿಯಾ | ಇಂಡೋನೇಷ್ಯಾ | ಜಪಾನ್ | ಭಾರತ | ರಷ್ಯಾ | ಫಿಲಿಪೈನ್ಸ್ | ಉಕ್ರೇನ್ | ಸ್ವಿಟ್ಜರ್ಲೆಂಡ್ | ಫಿನ್ಲ್ಯಾಂಡ್ | ಲಕ್ಸೆಂಬರ್ಗ್ | ಐರ್ಲೆಂಡ್ | ಎಸ್ಟೋನಿಯಾ | ರೊಮೇನಿಯಾ | ಬಲ್ಗೇರಿಯಾ | ಯುನೈಟೆಡ್ ಸ್ಟೇಟ್ಸ್ | ಕೀನ್ಯಾ | ಸೈಪ್ರಸ್ | ಗ್ರೀಸ್ | ಲಿಚ್ಟೆನ್‌ಸ್ಟೈನ್ | ಉಗಾಂಡಾ | ಸ್ವೀಡನ್ | ಗ್ರೇಟ್ ಬ್ರಿಟನ್ | ನೈಜರ್ | ಪಾಕಿಸ್ತಾನ | ಮಂಗೋಲಿಯಾ | ಪ್ಯಾಲೆಸ್ಟೈನ್ | ಅರ್ಮೇನಿಯಾ | ಆಸ್ಟ್ರಿಯಾ | ಆಸ್ಟ್ರೇಲಿಯಾ | ಕೆನಡಾ | ಡೆನ್ಮಾರ್ಕ್ | ಅಲ್ಜೀರಿಯಾ | ಘಾನಾ | ಕ್ರೊಯೇಷಿಯಾ | ಹಂಗೇರಿ | ಕಾಂಬೋಡಿಯಾ | ಶ್ರೀಲಂಕಾ | ಲಿಥುವೇನಿಯಾ | ಲಾಟ್ವಿಯಾ | ಮಾಲ್ಟಾ | ನ್ಯೂಜಿಲೆಂಡ್ | ಸೀಶೆಲ್ಸ್ | ಸಿಂಗಾಪುರ | ಸ್ಲೋವಾಕಿಯಾ | ದಕ್ಷಿಣ ಆಫ್ರಿಕಾ | ಅಂಡೋರಾ | ಜಾಂಬಿಯಾ | ಮಾರಿಷಸ್ | ತಾಂಜಾನಿಯಾ | ಬ್ರಿಟಿಷ್ ವರ್ಜಿನ್ ದ್ವೀಪಗಳು | ಟೋಗೋ | ಅಜೆರ್ಬೈಜಾನ್ | ಮೊಲ್ಡೊವಾ | ಸ್ಲೊವೇನಿಯಾ | ಬೆಲೀಜ್ | ಕಝಾಕಿಸ್ತಾನ್ | ಕಿರ್ಗಿಸ್ತಾನ್ | ಸರ್ಬಿಯಾ | ಉಜ್ಬೇಕಿಸ್ತಾನ್ | ಬೆಲಾರಸ್ | ಗಿನಿಯಾ | ಜಾರ್ಜಿಯಾ | ಬೋಸ್ನಿಯಾ ಮತ್ತು ಹರ್ಜೆಗೋವಿನಾ | ಜೋರ್ಡಾನ್ | ಕುವೈತ್ | ಕೊಸೊವೊ | ಅಲ್ಬೇನಿಯಾ | ಮೊಜಾಂಬಿಕ್ | ಅಫ್ಘಾನಿಸ್ತಾನ | ತಜಕಿಸ್ತಾನ್ | ಮಾಂಟೆನೆಗ್ರೊ | ಲಿಬಿಯಾ | ಕಾಂಗೋ-ಕಿನ್ಶಾಸಾ | ಲೆಬನಾನ್ | ಜಿಂಬಾಬ್ವೆ | ಸಿರಿಯಾ | ಮಾಲಿ | ಭೂತಾನ್ | ಈಕ್ವಟೋರಿಯಲ್ ಗಿನಿಯಾ | ರುವಾಂಡಾ | ಮಲಾವಿ | ಮ್ಯಾನ್ಮಾರ್ | ಬೋಟ್ಸ್ವಾನ | ಉತ್ತರ ಮ್ಯಾಸಿಡೋನಿಯಾ | ಬುರುಂಡಿ | ಜಮೈಕಾ | ಇಥಿಯೋಪಿಯಾ | ನ್ಯೂ ಕ್ಯಾಲೆಡೋನಿಯಾ | ಸಿಯೆರಾ ಲಿಯೋನ್ | ನಮೀಬಿಯಾ | ಲಾವೋಸ್ | ಟಿಮೋರ್-ಲೆಸ್ಟೆ | ಮಾಲ್ಡೀವ್ಸ್ | ಹೈಟಿ | ಬುರ್ಕಿನಾ ಫಾಸೊ | ಓಮನ್ | ಬಹಾಮಾಸ್ | ಸೊಮಾಲಿಯಾ | ಬಾರ್ಬಡೋಸ್ | ಗ್ರೆನಡಾ | ಪಪುವಾ ನ್ಯೂ ಗಿನಿಯಾ | ಜರ್ಸಿ | ಫಿಜಿ | ಸ್ಯಾನ್ ಮರಿನೋ | ಫ್ರೆಂಚ್ ಪಾಲಿನೇಷ್ಯಾ | ಟ್ರಿನಿಡಾಡ್ ಮತ್ತು ಟೊಬಾಗೊ | ಸುರಿನಾಮ್ | ಲೆಸೊಥೊ | ಎರಿಟ್ರಿಯಾ | ಸೇಂಟ್ ಲೂಸಿಯಾ | ಕೇಮನ್ ದ್ವೀಪಗಳು | ಅಂಗೋಲಾ | ಗ್ಯಾಂಬಿಯಾ | ಸ್ವಾಜಿಲ್ಯಾಂಡ್ | ಮಡಗಾಸ್ಕರ್ | ಲೈಬೀರಿಯಾ | ಮಾರಿಟಾನಿಯ | ಗಯಾನಾ | ವನವಾಟು | ಚಾಡ್ | ಟಾಂಗಾ | ಬರ್ಮುಡಾ | ತುರ್ಕಮೆನಿಸ್ತಾನ್ | ಸಮೋವಾ | ಜಿಬೌಟಿ | ಕೊಮೊರೊಸ್ | ವ್ಯಾಟಿಕನ್ ನಗರ | ಡೊಮಿನಿಕಾ | ಕೇಪ್ ವರ್ಡೆ | ಮಧ್ಯ ಆಫ್ರಿಕಾದ ಗಣರಾಜ್ಯ | ಸೊಲೊಮನ್ ದ್ವೀಪಗಳು | ಸಿಂಟ್ ಮಾರ್ಟನ್ |
MicroCloud Hologram Inc. Develops GHZ State and W State Transmission Scheme Based on Brownian State Quantum Channel
SHENZHEN, China, Feb. 6, 2026 /PRNewswire/ -- MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, developed a transmission scheme for GHZ states and W states based on Brownian state quantum channels. This scheme establishes an efficient transmission mechanism for multi-particle entangled states by constructing special quantum channels and measurement systems. At the technical implementation level, HOLO uses quantum Fourier transform for quantum state projection measurement and precisely designs the sequence of quantum gate operations required for reconstructing quantum states at the receiving end. This technical scheme not only perfects the theoretical system of quantum teleportation but also provides new technical paths for information transmission in large-scale quantum systems, promoting the development of quantum communication technology toward practicalization. In terms of technical architecture design, the implementation of the Brownian state quantum channel demonstrates significant innovation. The Brownian state is a special four-particle entangled state, whose characteristics are very suitable for constructing quantum transmission channels. HOLO utilizes this entanglement characteristic to establish stable quantum links. When transmitting the three-particle GHZ state, the sender performs joint measurement on the quantum state to be transmitted and specific particles in the Brownian state, which establishes quantum correlation between the transmission state and the channel state. The key to technical implementation lies in using specially designed measurement devices to make the measurement results form a definite correspondence with the channel state. This design enables the receiver to select the corresponding quantum gate operations to reconstruct the original quantum state based on the measurement results transmitted through the classical channel. The quantum Fourier transform plays a key role in this protocol, and its technical implementation has unique advantages. The research team adopts the quantum Fourier transform to construct the basic measurement framework required for projection measurement; this method has better system adaptability compared to traditional measurement methods. Through this mathematical transformation method, researchers can map quantum states to a set of standard measurement bases, thereby achieving accurate measurement of quantum states. In actual operation, this transformation is realized through an ordered combination of a series of quantum logic gates, and its system complexity maintains a reasonable relationship with the number of qubits, ensuring the scalability of the scheme. In the design and implementation stage of quantum gate operations, HOLO has established complete technical specifications. Based on quantum mechanics principles, the research team accurately calculates all quantum gate operations that the receiving end needs to execute to reconstruct the quantum state. For the transmission of GHZ states, these operations include the combined application of specific types of phase gates and controlled-NOT gates; whereas for the transmission of W states, it is necessary to implement more complex multi-particle control operations. Technical documents show that all quantum gate operations can be represented using a standard quantum gate set; this representation method simplifies the operation process and facilitates implementation on different quantum hardware platforms. The research team has also verified the feasibility of these quantum gate operations on superconducting quantum processors; through precise regulation of the electromagnetic control signals of qubits, the required quantum logic operations can be reliably realized. From the perspective of technical application prospects, this protocol has broad application potential in the field of quantum communication. The use of quantum Fourier transform makes the construction of measurement bases more systematic and standardized, and this characteristic is advantageous for unified implementation on different quantum hardware platforms. In quantum network architectures, this protocol can be used to build core transmission modules for distributed quantum computing, realizing the transmission of quantum information between different computing nodes. In addition, HOLO has also explored application schemes for this technology in specific scenarios such as quantum secure communication and distributed quantum measurement. With the continuous advancement of quantum hardware technology, particularly the continuous improvement in qubit performance and quantity, this transmission protocol is expected to play an important role in future quantum information systems, providing key technical support for building large-scale quantum networks. About MicroCloud Hologram Inc. MicroCloud Hologram Inc. (NASDAQ: HOLO) is committed to the research and development and application of holographic technology. Its holographic technology services include holographic light detection and ranging (LiDAR) solutions based on holographic technology, holographic LiDAR point cloud algorithm architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology, providing services to customers offering holographic advanced driving assistance systems (ADAS). MicroCloud Hologram Inc. provides holographic technology services to global customers. MicroCloud Hologram Inc. also provides holographic digital twin technology services and owns proprietary holographic digital twin technology resource libraries. Its holographic digital twin technology resource library utilizes a combination of holographic digital twin software, digital content, space data-driven data science, holographic digital cloud algorithms, and holographic 3D capture technology to capture shapes and objects in 3D holographic form. MicroCloud Hologram Inc. focuses on developments such as quantum computing and quantum holography, with cash reserves exceeding 3 billion RMB, and plans to invest more than 400 million in USD from the cash reserves to engage in blockchain development, quantum computing technology development, quantum holography technology development, and derivatives and technology development in frontier technology fields such as artificial intelligence AR. MicroCloud Hologram Inc.'s goal is to become a global leading quantum holography and quantum computing technology company. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission ("SEC"), including the Company's most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
2026-02-06 13:00:00

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals Validated system provides reliable, consistent carbon footprint data for clients INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This reflects the company's advanced and systematically developed approach to carbon accounting across biopharmaceutical manufacturing processes, supporting transparency and consistency in sustainability reporting. The validation was conducted by DNV, an independent assurance and risk management provider headquartered in Norway. DNV assessed the validity of the company's PCF system across data input, conversion, and output, confirming that the assumptions, methods, and overall approach follow globally accepted practices. Through this validated PCF framework, Samsung Biologics aims to support clearer communication and greater comparability of product-level carbon footprint data across the biopharmaceutical value chain, in line with evolving client expectations and sustainability requirements. "Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients," said John Rim, President and CEO of Samsung Biologics. "This represents the company's continued focus on building sustainable operations based on established standards, while maintaining reliable and consistent manufacturing. As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners." Samsung Biologics' sustainability efforts have also been recognized through its recent EcoVadis assessment, where the company received a Platinum rating, placing it among the top one percent of companies evaluated globally for sustainability management. For more information on Samsung Biologics' sustainability efforts, please visit the company's website. About Samsung Biologics Co., Ltd. Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenSTM framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, visit https://samsungbiologics.com/. Media Contact Claire Kim, Senior Director cair.kim@samsung.com Becky Lee, Director brite.lee@samsung.com
2026-02-06 13:00:00

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company's Cambridge, Massachusetts office. In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico's oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company's growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies. Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials. She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration. Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth. "Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico's oncology programs," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients." "I am excited to join Insilico Medicine at such an important stage of growth," said Dr. Zhang. "Insilico's unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients." Over the past year, Insilico Medicine's oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential "best-in-class" inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy. In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico's AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor. Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround - from project initiation to preclinical candidate (PCC) nomination - of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program. About Insilico Medicine Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.
2026-02-06 13:00:00

(新春见闻)2026年粤港澳大湾区灯会亮灯调试
2月6日,粤港澳大湾区灯会《南沙花神》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《李白对月》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《青花戏律》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《星河驰骋·骏马腾云》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《大唐盛世》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄 2月6日,粤港澳大湾区灯会《活力全运会》灯组亮灯调试。2026年粤港澳大湾区灯会将于2月10日正式亮灯迎客。本届灯会主会场设于广州南沙天后宫景区及滨海公园,设置五大主题展区,展出百组大型灯景及万盏彩灯。中新社记者 陈骥旻 摄
2026-02-06 12:59:49

鸿蒙智行新款尊界 S800 申报:增程器动力升级至 127 千瓦
IT之家 2 月 6 日消息,江淮今日有两款新的尊界 S800 车型通过了工信部申报,主要是对增程器进行了升级,功率从 125 千瓦升级至 127 千瓦。外观方面,尊界 S800 采用天地人和的设计理念,纵横星瀚的全新设计语言,配备了星汉灿烂大灯、星云画卷尾灯、摘星门把手。IT之家注意到,新车尾部采用了溜背式的造型,搭配拥有星河元素的贯通式尾灯,灯组上还镶嵌了 MAEXTRO 尊界的 LOGO。工信部信息显示,新车长宽高分别为 5480mm×2000mm×1536mm,轴距为 3370mm,采用 255/45 R20、265/45 R20,265/40 R21 轮胎。两款车型总质量均为 3270kg,整备质量分别为:2700/2770/2800/2810/2830kg2804/2822/2851/2865/2870kg悬架方面,新车拥有前双叉臂,后五连杆设计。同时,还配备了双腔空气悬架、连续可变阻尼减振器、多轮转向控制。动力方面,新车将搭载 127kW 增程器(排量 1498ml),双版本电机分别为:驱动电机峰值功率(前 / 后):160kW/230kW。M8100PHD 发动机最大净功率为 122kW, 对应的油耗为 0.15L/100km (整备质量 2700kg)、0.10L/100km (整备质量 2770kg,2810kg)、0.17L/100km (整备质量 2800kg,2830kg)。驱动电机峰值功率(前 / 后左 / 后右):160kW/237.5kW/237.5kW。M8100PHD 发动机最大净功率为 122kW, 对应的油耗为 0.18L/100km (整备质量 2804kg,2822kg,2865kg)、0.23L/100km (整备质量 2851kg,2870kg)。新车将搭载 63.262kWh 电池,纯电续航:271/258km315/311/302km
2026-02-06 12:58:23

Qatar Airways Partners with Michelin One-Star Filipino Chef Jordy and May Navarra to Launch an Exclusive Business Class Menu
Available from February, the new menu brings a modern take on Filipino cuisine to Business Class passengers flying from Manila to Doha MANILA, Philippines, Feb. 2, 2026 /PRNewswire/ -- Qatar Airways is proud to announce its latest collaboration with renowned Filipino husband-and-wife duo, Chef Jordy and May Navarra, featuring an exclusive new Business Class menu for passengers travelling from Manila to Doha. Available from 2 February, the menu features a modern and refined take on well-loved Filipino dishes, and starting July 2026, the menu will also be available from Doha to Manila. Qatar Airways Partners with Michelin One-Star Filipino Chef Jordy and May Navarra to Launch an Exclusive Business Class Menu As the head chef and owner behind Manila's One-Star Michelin Restaurant, Toyo Eatery, Chef Jordy Navarra brings his passion and love for cooking to Qatar Airways, with a five-course experience that reimagines fine-dining in the skies. The menu features an appetizer of seared chilled scallops, braised beef short ribs tiyula itum for main course, pansit noodle ensalada for a light option, purée of arroz caldo for breakfast porridge and a standout dessert of sans rival cake with philippine chocolate sorbet. Ingredients are carefully sourced from local suppliers, in accordance with sustainable practices and seasonality to highlight the best Filipino ingredients. This collaboration marks another milestone in Qatar Airways' award-winning in-flight offerings and its ongoing legacy of extraordinary gourmet offerings. By investing in premium onboard experiences and joining with world-class chefs, Qatar Airways has earned a reputation as a global leader in aviation. The airline was named the 'World's Best Business Class' for the 11th time in 2024 and achieved the title of 'World's Best Airline' for a record-breaking 8th time in the same year. Synonymous with luxury and innovation, Qatar Airways also holds accolades for 'World's Best Business Class Lounge' and 'Best Airline in the Middle East'. Qatar Airways currently flies to over 170 destinations worldwide, via one seamless connection through Hamad International Airport, the 'World's Best Airport', as voted by Skytrax in 2021, 2022, and 2024. Qatar Airways x Chef Jordy and May Menu: Manila – Doha Menu Appetizer Seared Chilled Scallopmustard leaf, shrimp buro, radish and salted egg Main Course Braised Beef Short Ribs Tiyula Itumcharred coconut, eggplant and heirloom Tinawon rice Dessert Sans Rival CakePhilippine chocolate sorbet Light Option Pansit Noodle Ensaladachayote and pomelo Breakfast Porridge Puree of Arroz Caldochicken, anchovy and egg Click here to download hi-res images About Qatar AirwaysA multiple award-winning airline, Qatar Airways won the 'World's Best Airline' title for an unprecedented ninth time at the 2025 World Airline Awards, managed by the international air transport rating organisation, Skytrax. Qatar Airways was previously named the World's Best Airline in 2011, 2012, 2015, 2017, 2019, 2021, 2022, and 2024. The airline continues to be synonymous with excellence, and has yet again received recognition for 'World's Best Business Class', and 'World's Best Business Class Airline Lounge'. As the leading connector in the region, Qatar Airways has also been lauded with the 'Best Airline in the Middle East' title for the 13 time. Qatar Airways currently flies to over 170 destinations worldwide, connecting through its Doha hub, Hamad International Airport, the 'Best Airport in the Middle East' for 11 consecutive years, as well as 'World's Best Airport Shopping' for the third year in a row, as voted by Skytrax. Hamad International Airport has previously been named the 'World's Best Airport' by Skytrax in 2021, 2022, and 2024. Qatar Airways was the first Airline in the Middle East to be certified to the highest level of IATA's Environmental Assessment (IEnvA) programme, based on recognised environmental management system principles (such as ISO 14001). As an inaugural signatory to the Buckingham Palace Declaration in March 2016, Qatar Airways became the first airline globally to be certified to the industry standard for the prevention of illegal wildlife trafficking in aviation. For further information, visit www.qatarairways.com
2026-02-02 07:09:00

0.050920009613037


ಸುದ್ದಿ
ಸುದ್ದಿ
ಚೀನಾ
ಸುದ್ದಿ
ಚೀನಾ
ಸುದ್ದಿ